Spots Global Cancer Trial Database for relapsed or refractory multiple myeloma
Every month we try and update this database with for relapsed or refractory multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma | NCT04194931 | Relapsed or Ref... | Autologous BCMA... | 18 Years - 70 Years | The First Affiliated Hospital of Nanchang University | |
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT06232707 | Multiple Myelom... | Alnuctamab Pomalidomide Daratumumab Elotuzumab Carfilzomib Dexamethasone | 18 Years - | Celgene | |
| Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | NCT05408026 | Relapsed or Ref... | Daratumumab Pomalidomide | 18 Years - | Alliance Foundation Trials, LLC. | |
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | NCT04706936 | Relapsed or Ref... | anti-BCMA CAR-T Cyclophosphamid Fludarabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Selinexor, Cyclophosphamide and Prednisone in Myeloma | NCT06212596 | Relapsed or Ref... | Selinexor Cyclophosphamid... Prednisone | 18 Years - | University of Leeds | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | NCT05927571 | Relapsed or Ref... | Cevostamab Elranatamab Tocilizumab | 18 Years - | Genentech, Inc. | |
| A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | NCT03815383 | Relapsed or Ref... | C-CAR088 | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients | NCT00401011 | Multiple Myelom... Multiple Myelom... | Perifosine Bortezomib Dexamethasone | 18 Years - | AEterna Zentaris | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | NCT06208150 | Relapsed or Ref... | Talquetamab Pomalidomide Teclistamab Elotuzumab Dexamethasone Bortezomib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | NCT03512353 | Relapsed or Ref... | Dexamethasone Carfilzomib | 18 Years - | Amgen | |
| Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | NCT05463939 | Relapsed or Ref... | Teclistamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | NCT05552976 | Relapsed or Ref... | Mezigdomide Carfilzomib Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | NCT05647512 | Relapsed or Ref... Other Plasma Ce... | LM-305 Dexamethasone | 18 Years - | LaNova Medicines Limited | |
| A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma | NCT01309412 | Multiple Myelom... | Siltuximab | 20 Years - | Janssen Pharmaceutical K.K. | |
| YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma | NCT05913804 | Relapsed or Ref... | YTS104 Cells in... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | NCT00478777 | Relapsed or Ref... | Lenalidomide dexamethasone | 18 Years - | Celgene | |
| CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT04626752 | Relapsed or Ref... | BCMA CAR-T Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| Study of BEBT-908 in Subjects With Advanced Hematological Tumors | NCT06082596 | Relapsed or Ref... Relapsed or Ref... | BEBT-908 for in... | 18 Years - 70 Years | BeBetter Med Inc | |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | NCT05455320 | Relapsed or Ref... | Talquetamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies | NCT04684108 | Relapsed or Ref... Hematological M... | SG301 | 18 Years - | Hangzhou Sumgen Biotech Co., Ltd. | |
| A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma | NCT01371227 | Multiple Myelom... | JNS002 | 20 Years - | Janssen Pharmaceutical K.K. | |
| Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma | NCT06375044 | Relapsed or Ref... | SIM0500 | 18 Years - | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan | NCT06163040 | Relapsed or Ref... | Elotuzumab in c... Elotuzumab in c... | 18 Years - | Bristol-Myers Squibb | |
| A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan | NCT06163040 | Relapsed or Ref... | Elotuzumab in c... Elotuzumab in c... | 18 Years - | Bristol-Myers Squibb | |
| YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma | NCT05913804 | Relapsed or Ref... | YTS104 Cells in... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | NCT05572515 | Relapsed or Ref... | Teclistamab Pomalidomide Bortezomib Dexamethasone Carfilzomib | 18 Years - | Janssen Research & Development, LLC | |
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | NCT04706936 | Relapsed or Ref... | anti-BCMA CAR-T Cyclophosphamid Fludarabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | NCT05455320 | Relapsed or Ref... | Talquetamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma | NCT05503550 | Relapsed or Ref... | Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) | NCT00642954 | Relapsed or Ref... | Vorinostat Lenalidomide Dexamethasone | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | NCT05652335 | Relapsed or Ref... Previously Trea... | JNJ-79635322 | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | NCT03512353 | Relapsed or Ref... | Dexamethasone Carfilzomib | 18 Years - | Amgen | |
| Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM | NCT05052970 | Relapsed or Ref... | Mitoxantrone Hy... Bortezomib for ... Dexamethasone A... | 18 Years - 75 Years | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | |
| Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | NCT00594126 | Multiple Myelom... | Imetelstat Sodi... | 18 Years - | Geron Corporation | |
| YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma | NCT05913804 | Relapsed or Ref... | YTS104 Cells in... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03859427 | Relapsed or Ref... | Carfilzomib Carfilzomib Lenalidomide Dexamethasone | 18 Years - 99 Years | Amgen | |
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | NCT06055075 | Relapsed or Ref... | Forimtamig Carfilzomib Daratumumab | 18 Years - | Hoffmann-La Roche | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | NCT06208150 | Relapsed or Ref... | Talquetamab Pomalidomide Teclistamab Elotuzumab Dexamethasone Bortezomib | 18 Years - | Janssen Research & Development, LLC | |
| Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | NCT00773838 | Relapsed or Ref... | Vorinostat Bortezomib Dexamethasone | 18 Years - | Merck Sharp & Dohme LLC | |
| mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT05918250 | Relapsed or Ref... | mRNA-2736 | 18 Years - | ModernaTX, Inc. | |
| Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma | NCT06375044 | Relapsed or Ref... | SIM0500 | 18 Years - | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | NCT05572515 | Relapsed or Ref... | Teclistamab Pomalidomide Bortezomib Dexamethasone Carfilzomib | 18 Years - | Janssen Research & Development, LLC | |
| INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | NCT03837509 | Relapsed or Ref... | INCB001158 Daratumumab SC | 18 Years - | Incyte Corporation | |
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | NCT06055075 | Relapsed or Ref... | Forimtamig Carfilzomib Daratumumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT05519085 | Relapsed or Ref... | mezigdomide Pomalidomide Bortezomib Dexamethasone | 18 Years - | Celgene | |
| A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | NCT06232096 | Relapsed or Ref... | MBS314 Injectio... | 18 Years - | Beijing Mabworks Biotech Co., Ltd. | |
| Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | NCT00773838 | Relapsed or Ref... | Vorinostat Bortezomib Dexamethasone | 18 Years - | Merck Sharp & Dohme LLC | |
| Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma | NCT05064358 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | NCT03110562 | Multiple Myelom... | Selinexor Bortezomib Dexamethasone | 18 Years - | Karyopharm Therapeutics Inc | |
| Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma | NCT05503550 | Relapsed or Ref... | Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| Selinexor, Cyclophosphamide and Prednisone in Myeloma | NCT06212596 | Relapsed or Ref... | Selinexor Cyclophosphamid... Prednisone | 18 Years - | University of Leeds | |
| Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM | NCT05052970 | Relapsed or Ref... | Mitoxantrone Hy... Bortezomib for ... Dexamethasone A... | 18 Years - 75 Years | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | |
| A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma | NCT05011097 | Relapsed or Ref... | Y150 | 18 Years - | Wuhan YZY Biopharma Co., Ltd. | |
| Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | NCT00718601 | Multiple Myelom... | Imetelstat Sodi... | 18 Years - | Geron Corporation | |
| Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | NCT00773838 | Relapsed or Ref... | Vorinostat Bortezomib Dexamethasone | 18 Years - | Merck Sharp & Dohme LLC | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience | |
| Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | NCT05565807 | Relapsed or Ref... | STI-6129 | 18 Years - | Zhejiang ACEA Pharmaceutical Co. Ltd. | |
| Study of BEBT-908 in Subjects With Advanced Hematological Tumors | NCT06082596 | Relapsed or Ref... Relapsed or Ref... | BEBT-908 for in... | 18 Years - 70 Years | BeBetter Med Inc | |
| A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma | NCT05920876 | Relapsed or Ref... | QLS32015 | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | NCT00718601 | Multiple Myelom... | Imetelstat Sodi... | 18 Years - | Geron Corporation | |
| A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04939142 | Relapsed or Ref... | SVd (Selinexor+... Vd (Bortezomib+... | 18 Years - | Antengene Corporation | |
| A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma | NCT01145989 | Multiple Myelom... | AT9283 | 18 Years - | Canadian Cancer Trials Group | |
| Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma | NCT02075021 | Relapsed or Ref... | Lenalidomide nab-paclitaxel | 18 Years - | NYU Langone Health | |
| Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | NCT00675428 | Multiple Myelom... | BG00002 (natali... | 18 Years - | Biogen | |
| Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | NCT05408026 | Relapsed or Ref... | Daratumumab Pomalidomide | 18 Years - | Alliance Foundation Trials, LLC. | |
| Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | NCT05227144 | Relapsed or Ref... | ORIC-533 | 18 Years - | ORIC Pharmaceuticals | |
| Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma | NCT02939183 | Relapsed or Ref... | Immediate Relea... Gastro-Retentiv... Dexamethasone Pomalidomide | 18 Years - 100 Years | Amgen | |
| Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | NCT05463939 | Relapsed or Ref... | Teclistamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | NCT03751293 | Relapsed or Ref... | C-CAR088 | 18 Years - 70 Years | Hebei Yanda Ludaopei Hospital | |
| A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | NCT05714839 | Multiple Myelom... | Bela Belamaf Lenalidomide Dexamethasone Standard of Car... | 18 Years - | GlaxoSmithKline | |
| BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) | NCT02834364 | Relapsed or Ref... Patients With B... | Encorafenib Binimetinib | 18 Years - | University of Heidelberg Medical Center | |
| A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04939142 | Relapsed or Ref... | SVd (Selinexor+... Vd (Bortezomib+... | 18 Years - | Antengene Corporation | |
| A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | NCT05714839 | Multiple Myelom... | Bela Belamaf Lenalidomide Dexamethasone Standard of Car... | 18 Years - | GlaxoSmithKline | |
| AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia | NCT02675452 | Relapsed or Ref... Relapsed or Ref... | AMG 176 Azacitidine Itraconazole | 18 Years - 85 Years | Amgen | |
| A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03859427 | Relapsed or Ref... | Carfilzomib Carfilzomib Lenalidomide Dexamethasone | 18 Years - 99 Years | Amgen | |
| Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide | NCT02046915 | Relapsed or Ref... | Imnovid (pomali... Dexamethasone Endoxan (Cyclop... | 18 Years - 99 Years | University Hospital Tuebingen | |
| To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | NCT06298266 | Relapsed or Ref... | infusion of GPR... | 18 Years - 75 Years | Guangdong Second Provincial General Hospital | |
| A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function | NCT04398680 | Multiple Myelom... | Belantamab mafo... | 18 Years - | GlaxoSmithKline | |
| Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | NCT05007418 | Multiple Myelom... | STI-1492 | 18 Years - | Sorrento Therapeutics, Inc. | |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | NCT05652335 | Relapsed or Ref... Previously Trea... | JNJ-79635322 | 18 Years - | Janssen Research & Development, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
